Takeda Pharmaceutical/$TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Tokyo, Japan
Employees
49,281
ISIN
US8740602052
Website
TAK Metrics
BasicAdvanced
$46B
32.21
$0.46
0.26
$0.51
3.59%
Price and volume
Market cap
$46B
Beta
0.26
52-week high
$15.43
52-week low
$12.58
Average daily volume
2.2M
Dividend rate
$0.51
Financial strength
Current ratio
1.006
Quick ratio
0.443
Long term debt to equity
65.127
Total debt to equity
73.042
Dividend payout ratio (TTM)
280.28%
Interest coverage (TTM)
4.15%
Profitability
EBITDA (TTM)
8,328.323
Gross margin (TTM)
65.51%
Net profit margin (TTM)
2.36%
Operating margin (TTM)
9.80%
Effective tax rate (TTM)
38.23%
Revenue per employee (TTM)
$639,630
Management effectiveness
Return on assets (TTM)
1.91%
Return on equity (TTM)
1.52%
Valuation
Price to earnings (TTM)
32.213
Price to revenue (TTM)
0.746
Price to book
0.98
Price to tangible book (TTM)
-3.37
Price to free cash flow (TTM)
4.821
Free cash flow yield (TTM)
20.74%
Free cash flow per share (TTM)
309.07%
Dividend yield (TTM)
3.39%
Forward dividend yield
3.59%
Growth
Revenue change (TTM)
7.45%
Earnings per share change (TTM)
-26.25%
3-year revenue growth (CAGR)
8.68%
10-year revenue growth (CAGR)
9.93%
3-year earnings per share growth (CAGR)
-22.76%
10-year earnings per share growth (CAGR)
-9.65%
3-year dividend per share growth (CAGR)
2.88%
10-year dividend per share growth (CAGR)
0.86%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Bulls say / Bears say
Takeda's Growth & Launch Products delivered a 14.6% increase at constant exchange rates, indicating strong product momentum. (Takeda Pharmaceuticals)
The company raised its full-year profit forecast to 344 billion yen, reflecting strong product performance and operational efficiencies. (Reuters)
Takeda announced a share buyback of up to 1.8% of its shares worth 100 billion yen, demonstrating confidence in its financial position and commitment to shareholder returns. (Takeda Pharmaceuticals)
Takeda's shares have fallen about 10% since the Shire acquisition in May 2018, underperforming the benchmark Nikkei index, which is up more than 170% in the same period. (Reuters)
The company is undergoing restructuring, including layoffs and early retirement plans, which may lead to short-term operational disruptions. (Reuters)
Takeda has faced challenges in rebuilding its drug pipeline after losing patent protection on major earners and experiencing clinical trial failures, potentially impacting future revenue streams. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Business Wire·2 weeks ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Business Wire·3 weeks ago
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $46B as of June 20, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 32.21 as of June 20, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.50554 and the yield is 3.59%. Takeda Pharmaceutical has a payout ratio of 280.28% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.